{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:17Z","timestamp":1786997897327,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022876","name":"Photocure Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.111090","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:15:22Z","timestamp":1775247322000},"page":"70-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7086-1410","authenticated-orcid":false,"given":"Ali A.","family":"Nasrallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"De Hoedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Lapon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-2185","authenticated-orcid":false,"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.111090_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.111090_bib0002","series-title":"Biology of Bladder Cancer: From Molecular Insights to Clinical Strategies","first-page":"3","article-title":"Epidemiology of Bladder Cancer","author":"Nasrallah","year":"2025"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111090_bib0003","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s41669-024-00512-8","article-title":"Economic Impact of Bladder Cancer in the USA","volume":"8","author":"Clark","year":"2024","journal-title":"Pharmacoecon Open"},{"issue":"18","key":"10.1016\/j.urolonc.2026.111090_bib0004","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urolonc.2026.111090_bib0005","unstructured":"Institute, N.C. Financial Burden of Cancer Care. 2025 April 2025 [cited 2025 8\/30\/2025]; Available from: https:\/\/progressreport.cancer.gov\/after\/economic_burden."},{"issue":"4","key":"10.1016\/j.urolonc.2026.111090_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/cncr.33300","article-title":"Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort","volume":"127","author":"Garg","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111090_bib0007","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000260","article-title":"Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO Study","volume":"3","author":"Nasrallah","year":"2025","journal-title":"JU Open Plus"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111090_bib0008","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111090_bib0009","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111090_bib0010","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/01.ju.0000169257.19841.2a","article-title":"Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study","volume":"174","author":"Jocham","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111090_bib0011","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2005.02.003","article-title":"Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?","volume":"66","author":"Svatek","year":"2005","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111090_bib0012","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.juro.2012.03.007","article-title":"Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy","volume":"188","author":"Grossman","year":"2012","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111090_bib0013","article-title":"Blue versus white light for transurethral resection of non-muscle invasive bladder cancer","volume":"12","author":"Maisch","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111090_bib0014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3233\/BLC-160048","article-title":"The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis","volume":"2","author":"Kamat","year":"2016","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111090_bib0015","first-page":"6682","article-title":"The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation","volume":"20","author":"Garfield","year":"2013","journal-title":"Can J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111090_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5489\/cuaj.4568","article-title":"Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer","volume":"11","author":"Klaassen","year":"2017","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111090_bib0017","doi-asserted-by":"crossref","first-page":"10.e7","DOI":"10.1016\/j.urolonc.2021.05.023","article-title":"Macro and microeconomics of blue light cystoscopy with CYSVIEW\u00ae in non-muscle invasive bladder cancer","volume":"40","author":"Williams","year":"2022","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111090_bib0018","doi-asserted-by":"crossref","first-page":"711.e1","DOI":"10.1016\/j.clgc.2023.04.011","article-title":"The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence","volume":"21","author":"Das","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.111090_bib0019","unstructured":"U.S. Bureau of Labor Statistics. Consumer Price Index: 2023 in review. 2024 December 02, 2025; Available from: https:\/\/www.bls.gov\/opub\/ted\/2024\/consumer-price-index-2023-in-review.htm."},{"issue":"3","key":"10.1016\/j.urolonc.2026.111090_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6b","key":"10.1016\/j.urolonc.2026.111090_bib0021","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.1111\/bju.13261","article-title":"Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden","volume":"117","author":"Rose","year":"2016","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111090_bib0022","doi-asserted-by":"crossref","first-page":"207.e9","DOI":"10.1016\/j.urolonc.2022.11.014","article-title":"Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?","volume":"41","author":"Shore","year":"2023","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111090_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Gu\u00e9rin in the Veterans Affairs Health System","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111090_bib0024","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200092","article-title":"A Randomized Trial of PHOTOdynamic Surgery in Non-Muscle-Invasive Bladder Cancer","volume":"1","author":"Heer","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111090_bib0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.4917","article-title":"Racial inequity and other social disparities in the diagnosis and management of bladder cancer","volume":"12","author":"Hasan","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111090_bib0026","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clgc.2023.05.016","article-title":"The Risk of Catastrophic Healthcare Expenditures Among Prostate and Bladder Cancer Survivors in the United States","volume":"21","author":"Stone","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111090_bib0027","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.16380","article-title":"Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system","volume":"134","author":"Bree","year":"2024","journal-title":"BJU Int"},{"issue":"21","key":"10.1016\/j.urolonc.2026.111090_bib0028","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1002\/cncr.33792","article-title":"The impact of the social construct of race on outcomes among bacille Calmette-Gu\u00e9rin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting","volume":"127","author":"Lawler","year":"2021","journal-title":"Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:28:35Z","timestamp":1778200115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1078143926001018"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111090","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}